Psychological burden of haematological cancer on patient and family: is it time for a multisystem approach?
Purpose of review Literature addressing the psychological impact of haematological cancers on patients and their families is sparse. New evidence might prompt a change in approach to the assessment and management of psychological burden. Recent findings The diagnosis, treatment and surveillance of haematological cancers often have a profound psychological impact on patients and their families and can result in clinically significant problems and increased carer stress. These may manifest at any stage from diagnosis to death or living as a survivor. Some high-risk subgroups have been identified. Summary The range of diagnostic groups, wide range of data analysis time-points relative to time of diagnosis, heterogeneity of outcome measures and differing methodologies (mainly prevalence studies) confound generalization of the findings. Targeted screening of the most at-risk subpopulations at times of greatest risk seems sensible to facilitate early intervention; further work is required to establish how often to screen and the best way of doing that. None of these articles define thresholds for intervention. Clearly more psychological support is needed for patients with haematological cancers and their families, but these articles do not provide evidence to suggest what this should comprise. There remains a need for large, longitudinal multicentre studies.
ConclusionIncreasing patient age and caregiver ’s perceived spousal support may both have a positive effect on caregivers’ levels of depression. This can be utilized by clinicians in the process of empowering older patients and their spousal caregivers to confront the challenges of cancer treatment into advanced old age.
AbstractPurposeThe oldest old, described as those aged 85 and older, is a growing cancer population. There are limited studies evaluating the symptoms of the oldest old cancer patient population. Our study aimed to evaluate symptom frequency and clinical symptom change as assessed by the Edmonton Symptom Assessment System (ESAS) of the oldest old ( ≥ 85) compared to older adult (65–84) and general adult (18–64) outpatient cancer patients on initial consult and follow-up visit.MethodsRetrospective review of a total of 441 patients, 200 randomly sampled patients in the general and older adult group and ...
AbstractConstipation, one of the adverse effects of opioid therapy with a major impact on quality of life, is still an unmet need for cancer patients, particularly those with an advanced and progressive disease, and for non-cancer patients chronically treated with opioids. The awareness of this condition is poor among healthcare providers, despite the recent publication of guidelines and consensus conferences. An early multidisciplinary approach of opioid-induced bowel dysfunction (OIBD), based on available therapies of proven effectiveness, could support clinicians in managing this condition, thus increasing patients &rsq...
Conditions: Cancer; Palliative Radiotherapy Interventions: Radiation: Lattice stereotactic body radiation therapy; Procedure: Peripheral blood Sponsor: Washington University School of Medicine Not yet recruiting
ConclusionA new risk score system for patients with first recurrence of stage 4 neuroblastoma aged ≥18 months at diagnosis is proposed.
ConclusionsOverall, terminal dyspnea was relatively well controlled with parenteral morphine, though a significant number of patients continued to suffer from dyspnea. Future efforts are needed to improve outcomes following standardized dyspnea treatment using patient-reported outcomes for imminently dying patients.
Publication date: 19–25 October 2019Source: The Lancet, Volume 394, Issue 10207Author(s): Evelien Dekker, Pieter J Tanis, Jasper L A Vleugels, Pashtoon M Kasi, Michael B WallaceSummarySeveral decades ago, colorectal cancer was infrequently diagnosed. Nowadays, it is the world's fourth most deadly cancer with almost 900 000 deaths annually. Besides an ageing population and dietary habits of high-income countries, unfavourable risk factors such as obesity, lack of physical exercise, and smoking increase the risk of colorectal cancer. Advancements in pathophysiological understanding have increased the array of treatme...
The aim of this review was to examine efficacy of palliative interventional radiotherapy (IRT) in esophageal cancer compared with other treatment in terms of dysphagia-free survival (DyFS) and safety.
ConclusionsBevacizumab was the only prescribed targeted therapy in first-line treatment. Considering the limited number of patients receiving first-line bevacizumab and the unknown reasons to prescribe additional targeted therapy, the corresponding survival rates of patients treated with and without additional bevacizumab in first-line treatment might suggest a limited clinical effect of bevacizumab in addition to first-line palliative chemotherapy on OS. Future research should focus on identifying the subgroup of patients who might benefit OR benefiting from anti-VEGF therapy in metastatic SBA.
Authors: PMID: 31619049 [PubMed - as supplied by publisher]